相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Understanding the role of tariquidar, a potent Pgp inhibitor, in combination trials with cytotoxic drugs: What is missing?
Nuggehally R. Srinivas
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Whole-Body Distribution and Radiation Dosimetry of 11C-Elacridar and 11C-Tariquidar in Humans
Martin Bauer et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model
Rajendar K. Mittapalli et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases
Shruthi Vaidhyanathan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes
Yang Lu et al.
DRUG METABOLISM AND DISPOSITION (2016)
Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors
Elizabeth Fox et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
A model of secreting murine mammary epithelial HC11 cells comprising endogenous Bcrp/Abcg2 expression and function
Jonas Tallkvist et al.
CELL BIOLOGY AND TOXICOLOGY (2015)
P-Glycoprotein (ABCB1) Limits the Brain Distribution of YQA-14, a Novel Dopamine D3 Receptor Antagonist
Fei Liu et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2015)
ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors
Ping Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of 11C-Erlotinib
Alexander Traxl et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer
Teppei Sugano et al.
MOLECULAR CANCER THERAPEUTICS (2015)
P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice
Seng Chuan Tang et al.
MOLECULAR PHARMACEUTICS (2015)
Effect of drug efflux transporters on placental transport of antiretroviral agent abacavir
Zuzana Neumanova et al.
REPRODUCTIVE TOXICOLOGY (2015)
Efflux Transporters at the Blood-Brain Barrier Limit Delivery and Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib (PD-0332991) in an Orthotopic Brain Tumor Model
Karen E. Parrish et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Role of P-Glycoprotein in the Distribution of the HIV Protease Inhibitor Atazanavir in the Brain and Male Genital Tract
Kevin R. Robillard et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
J. J. M. A. Hendrikx et al.
BRITISH JOURNAL OF CANCER (2014)
Convallatoxin: A new P-glycoprotein substrate
Elnaz Gozalpour et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar
Seng Chuan Tang et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Estimation of the Unbound Brain Concentration of P-Glycoprotein Substrates or Nonsubstrates by a Serial Cerebrospinal Fluid Sampling Technique in Rats
T. Thanga Mariappan et al.
MOLECULAR PHARMACEUTICS (2014)
Role of P-Glycoprotein on the Brain Penetration and Brain Pharmacodynamic Activity of the MEK Inhibitor Cobimetinib
Edna F. Choo et al.
MOLECULAR PHARMACEUTICS (2014)
Inhibiting drug efflux transporters improves efficacy of ALS therapeutics
Michael R. Jablonski et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2014)
Coadministration of P-Glycoprotein Modulators on Loperamide Pharmacokinetics and Brain Distribution
Rita Nieto Montesinos et al.
DRUG METABOLISM AND DISPOSITION (2014)
Pharmacokinetic interactions between 20(S)-ginsenoside Rh2 and the HIV protease inhibitor ritonavir in vitro and in vivo
Jian Shi et al.
ACTA PHARMACOLOGICA SINICA (2013)
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias
Robert O'Connor et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues
Fan Lin et al.
CLINICAL CANCER RESEARCH (2013)
P-glycoprotein Inhibition Increases the Brain Distribution and Antidepressant-Like Activity of Escitalopram in Rodents
Fionn E. O'Brien et al.
NEUROPSYCHOPHARMACOLOGY (2013)
Transport Inhibition of Digoxin Using Several Common P-gp Expressing Cell Lines Is Not Necessarily Reporting Only on Inhibitor Binding to P-gp
Annie Albin Lumen et al.
PLOS ONE (2013)
Pharmacokinetics of Single Ascending Doses of the P-Glycoprotein Inhibitor Tariquidar in Healthy Subjects
M. Bauer et al.
PHARMACOLOGY (2013)
Function of the Blood-Brain Barrier and Restriction of Drug Delivery to Invasive Glioma Cells: Findings in an Orthotopic Rat Xenograft Model of Glioma
Sagar Agarwal et al.
DRUG METABOLISM AND DISPOSITION (2013)
Pharmacokinetic Assessment of Efflux Transport in Sunitinib Distribution to the Brain
Rajneet K. Oberoi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects
Joerg Koenig et al.
PHARMACOLOGICAL REVIEWS (2013)
Saturable Active Efflux by P-Glycoprotein and Breast Cancer Resistance Protein at the Blood-Brain Barrier Leads to Nonlinear Distribution of Elacridar to the Central Nervous System
Ramola Sane et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Simultaneous quantification of berberine and lysergol by HPLC-UV: evidence that lysergol enhances the oral bioavailability of berberine in rats
Shrikant Patil et al.
BIOMEDICAL CHROMATOGRAPHY (2012)
Interaction of innovative small molecule drugs used for cancer therapy with drug transporters
K. Mandery et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Investigational ABC transporter inhibitors
Marco Falasca et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration
Seng Chuan Tang et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors
Mukul Minocha et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2012)
Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib
Mukul Minocha et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2012)
Oral Availability and Brain Penetration of the B-RAFV600E Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar
Selvi Durmus et al.
MOLECULAR PHARMACEUTICS (2012)
Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-Glycoprotein
Britta Stordal et al.
PLOS ONE (2012)
Pharmacokinetic Modeling to Assess Factors Affecting the Oral Bioavailability of the Lactone and Carboxylate Forms of the Lipophilic Camptothecin Analogue AR-67 in Rats
Eyob D. Adane et al.
PHARMACEUTICAL RESEARCH (2012)
Brain Distribution and Bioavailability of Elacridar after Different Routes of Administration in the Mouse
Ramola Sane et al.
DRUG METABOLISM AND DISPOSITION (2012)
P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Restrict Brain Accumulation of the Active Sunitinib Metabolite N-Desethyl Sunitinib
Seng Chuan Tang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
The Bioflavonoid Kaempferol Is an Abcg2 Substrate and Inhibits Abcg2-Mediated Quercetin Efflux
Guohua An et al.
DRUG METABOLISM AND DISPOSITION (2011)
The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain
Sagar Agarwal et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Ixabepilone, a Novel Microtubule-Targeting Agent for Breast Cancer, Is a Substrate for P-Glycoprotein (P-gp/MDR1/ABCB1) but not Breast Cancer Resistance Protein (BCRP/ABCG2)
H. Shen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
Amanda J. O'Neill et al.
MOLECULAR CANCER (2011)
Evaluation of Drug Efflux Transporter Liabilities of Darifenacin in Cell Culture Models of the Blood-Brain and Blood-Ocular Barriers
Donald W. Miller et al.
NEUROUROLOGY AND URODYNAMICS (2011)
Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography
Tomoteru Yamasaki et al.
NUCLEAR MEDICINE AND BIOLOGY (2011)
Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999
Larry D. Cripe et al.
BLOOD (2010)
Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[11C]verapamil PET
Claudia Kuntner et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Perspectives of P-Glycoprotein Modulating Agents in Oncology and Neurodegenerative Diseases: Pharmaceutical, Biological, and Diagnostic Potentials
Nicola Antonio Colabufo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux
Sagar Agarwal et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment
Jurjen S. Lagas et al.
CLINICAL CANCER RESEARCH (2009)
The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib
Roos L. Oostendorp et al.
INVESTIGATIONAL NEW DRUGS (2009)
Comparison of Bidirectional Lamivudine and Zidovudine Transport Using MDCK, MDCK-MDR1, and Caco-2 Cell Monolayers
Jacqueline De Souza et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib
Ying Chen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [11C]gefitinib
Kazunori Kawamura et al.
NUCLEAR MEDICINE AND BIOLOGY (2009)
Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines
Takenori Takahata et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2008)
The solute carrier (SLC) complement of the human genome: Phylogenetic classification reveals four major families
Robert Fredriksson et al.
FEBS LETTERS (2008)
ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells
Xavier Decleves et al.
PHARMACOLOGICAL RESEARCH (2008)
Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters
J. A. Schrickx et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
P-glycoprotein and breast cancer resistance protein: Two dominant transporters working together in limiting the brain penetration of topotecan
Nienke A. de Vries et al.
CLINICAL CANCER RESEARCH (2007)
Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar
Sebastien Bihorel et al.
PHARMACEUTICAL RESEARCH (2007)
Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec®) across the mouse blood-brain barrier
Sebastien Bihorel et al.
JOURNAL OF NEUROCHEMISTRY (2007)
A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients
Isa E. L. M. Kuppens et al.
CLINICAL CANCER RESEARCH (2007)
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor
Elizabeth Fox et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new Polymer-Lipid Hybrid Nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer
Ho Lun Wong et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Role of human placental efflux transporter P-glycoprotein in the transfer of buprenorphine, levo-α-acetylmethadol, and paclitaxel
Ilona A. Nekhayeva et al.
AMERICAN JOURNAL OF PERINATOLOGY (2006)
The complexity of intestinal absorption and exsorption of digoxin in rats
Hsuan-Ming Yao et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2006)
Ochratoxin A secretion by ATP-dependent membrane transporters in Caco-2 cells
J Schrickx et al.
ARCHIVES OF TOXICOLOGY (2006)
Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line bewo
M Ceckova et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2006)
Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: Role of Mrp2 and Bcrp1
MJ Zamek-Gliszczynski et al.
DRUG METABOLISM AND DISPOSITION (2005)
Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours
LH Lê et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer
KN Chi et al.
INVESTIGATIONAL NEW DRUGS (2005)
Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells
CQ Xia et al.
DRUG METABOLISM AND DISPOSITION (2005)
The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients
P Breedveld et al.
CANCER RESEARCH (2005)
A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors
AST Planting et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: A minor role of breast cancer resistance protein
YJ Lee et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein
EM Kemper et al.
EUROPEAN JOURNAL OF CANCER (2004)
Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice
SB de Lagerie et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[ 2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey
KW Ward et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice
HA Bardelmeijer et al.
INVESTIGATIONAL NEW DRUGS (2004)
The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters
JW Polli et al.
DRUG METABOLISM AND DISPOSITION (2004)
A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy
A Sandler et al.
CLINICAL CANCER RESEARCH (2004)
P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement
MVS Varma et al.
PHARMACOLOGICAL RESEARCH (2003)
Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans
F Imbert et al.
DRUG METABOLISM AND DISPOSITION (2003)
Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir
MT Huisman et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
MDRI modulators improve the chemotherapy response of human hepatoblastoma to doxorubicin in vitro
S Warmann et al.
JOURNAL OF PEDIATRIC SURGERY (2002)
Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters PGP, cMOAT, and MRP1
FR Luo et al.
DRUG METABOLISM AND DISPOSITION (2002)
GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats
JE Edwards et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats
J Savolainen et al.
DRUG METABOLISM AND DISPOSITION (2002)
Isolation of endothelial cells from brain, lung, and kidney:: Expression of the multidrug resistance P-glycoprotein isoforms
M Demeule et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients
MM Malingré et al.
BRITISH JOURNAL OF CANCER (2001)
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan
JW Jonker et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein
K Westphal et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier
J Wijnholds et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
分享论文
